Verastem Inc.

5.70
-0.14 (-2.40%)
At close: Apr 03, 2025, 3:59 PM
5.68
-0.35%
After-hours: Apr 03, 2025, 04:07 PM EDT
-2.40%
Bid 5.4
Market Cap 293.47M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -3.66
PE Ratio (ttm) -1.56
Forward PE -2.13
Analyst Buy
Ask 5.84
Volume 666,240
Avg. Volume (20D) 904,490
Open 5.57
Previous Close 5.84
Day's Range 5.39 - 5.76
52-Week Range 2.10 - 13.52
Beta 0.60

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel coho...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 27, 2012
Employees 78
Stock Exchange NASDAQ
Ticker Symbol VSTM
Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for VSTM stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 145.61% from the latest price.

Stock Forecasts

Next Earnings Release

Verastem Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-20.12%
Verastem shares are trading lower. The company pre... Unlock content with Pro Subscription
6 months ago
+11.15%
Verastem shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a $13 price target.